The 2016 Seattle Genetics’ Financial Results Conference, which was directed by Corporate Communications Executive Director, Peggy Pinkston, highlighted the several achievements the company has made in the second quarter of the 2016 financial year. The items brought up for discussion included statements touching on the future financial events that may impact the financial performance of the company as well as enhancing conformity with the regulations offered by the SEC.
The form highlights some of the risk factors that could trigger actual results to differ from the ones present in forward-looking statements.
A word from the Chairman, Clay B. Siegall
The Executive Director of Communications finally handed over the debate to the Chairman, Clay Siegall, for closing remarks and for information about the financial progress of the company to this point. Clay B. Siegall emphasized in the need to build ADCETRIS to become an internationally accepted brand while also enhancing innovation and profitability for the company. He commended the progress of the company on this product and expressed hope in the creation of more products to accompany their mission on revolutionizing biotechnology.
Clay B. Siegall proceeded with his speech and noted the much progress they have made as a company in ensuring antitumor activity from the different ADCs they have released to the market is enhanced. In the second quarter alone, Seattle Genetics made $95.4 million in revenues, which included $66.2 million net revenue from ADCETRIS.
About Seattle Genetics and Chairman Clay B. Siegall
Seattle Genetics is a leading biotechnology firm that focuses on the development of antibody-based therapies that are useful in the treatment of cancer. The company, which is led by CEO and Board Chairman Clay B. Siegall, is among few that have introduced clinical trials and innovative technology.
Clay B. Siegall is a co-founder of Seattle Genetics and has been steering the company since its establishment in 1998. He is a scientist by training and his main areas of focus are cancer therapies. Clay B. Siegall has created a scientific foundation for Seattle Genetics and has encouraged rigorous research and product development practices.